April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Clinical Trial of Gene Therapy for Early Onset Severe Retinal Dystrophy Caused by Defects in RPE65
Author Affiliations & Notes
  • J. W. B. Bainbridge
    Moorfields/UCL Institute of Ophthalmology NIHR Biomedical Research Centre for Ophthalmology, London, United Kingdom
  • A. J. Smith
    Genetics, UCL Institute of Ophthalmology, London, United Kingdom
  • G. S. Rubin
    Moorfields/UCL Institute of Ophthalmology NIHR Biomedical Research Centre for Ophthalmology, London, United Kingdom
  • S. Robbie
    Moorfields/UCL Institute of Ophthalmology NIHR Biomedical Research Centre for Ophthalmology, London, United Kingdom
  • F. W. Fitzke
    Genetics, UCL Institute of Ophthalmology, London, United Kingdom
  • G. E. Holder
    Moorfields/UCL Institute of Ophthalmology NIHR Biomedical Research Centre for Ophthalmology, London, United Kingdom
  • A. Stockman
    Genetics, UCL Institute of Ophthalmology, London, United Kingdom
  • I. van den Born
    Rotterdam Eye Hospital, Rotterdam, The Netherlands
  • T. Moore
    Genetics,
    Moorfields/UCL Institute of Ophthalmology NIHR Biomedical Research Centre for Ophthalmology, London, United Kingdom
  • R. R. Ali
    Genetics,
    Moorfields/UCL Institute of Ophthalmology NIHR Biomedical Research Centre for Ophthalmology, London, United Kingdom
  • Footnotes
    Commercial Relationships  J.W.B. Bainbridge, 12/390,239, P; A.J. Smith, None; G.S. Rubin, None; S. Robbie, None; F.W. Fitzke, None; G.E. Holder, None; A. Stockman, None; I. van den Born, None; T. Moore, None; R.R. Ali, 12/390,239, P.
  • Footnotes
    Support  BRPS, Wellcome Trust, Moorfields Trustees, Sir Jules Thorn Trust, EPSRC, EVI Genoret and Clinigene, Targeted Genetics, MRC, FFB USA, Fight for Sight, Ulverscroft Found., Fighting Blindness Ireland
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4493. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. W. B. Bainbridge, A. J. Smith, G. S. Rubin, S. Robbie, F. W. Fitzke, G. E. Holder, A. Stockman, I. van den Born, T. Moore, R. R. Ali; Clinical Trial of Gene Therapy for Early Onset Severe Retinal Dystrophy Caused by Defects in RPE65. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4493.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Recombinant adeno-associated virus (rAAV) vector-mediated gene replacement therapy can improve retinal function and visual behaviour in human subjects with defects in the gene encoding the RPE isomerase RPE65. The purpose of this clinical trial is to further investigate the safety and efficacy of gene therapy for retinal dystrophy caused by RPE65 mutations.

Methods: : In a phase I/II dose-escalation trial, we have delivered subretinally recombinant adeno-associated virus (rAAV) vector expressing RPE65 under the control of an RPE65 promoter in 7 human subjects with early onset severe retinal dystrophy associated with mutations in RPE65. We have examined systemic vector dissemination and immune responses following vector delivery, assessed visual function pre- and post- vector delivery using a range of psychophysical techniques, and performed detailed electrophysiology and retinal imaging studies.

Results: : There have been no serious adverse effects of surgical delivery of vector in the subjects enrolled to date. We have detected no systemic dissemination of vector genome. We have detected an increase in systemic neutralising antibodies to AAV capsid in one subject but no evidence of immune responses to RPE65 proteins. We have measured significant improvements in retinal sensitivity by microperimetry and dark-adapted perimetry, and improved performance in a test of visually-guided mobility.

Conclusions: : The outcomes in the first 7 subjects to date suggest that subretinal delivery of rAAV vector can be safe in humans in the short term and can improve retinal sensitivity.

Clinical Trial: : www.clinicaltrials.gov NCT00643747

Keywords: gene transfer/gene therapy • retinal degenerations: hereditary 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×